Biomea Fusion Inc
NASDAQ:BMEA
Biomea Fusion Inc
Total Current Liabilities
Biomea Fusion Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Total Current Liabilities
$21.7m
|
CAGR 3-Years
68%
|
CAGR 5-Years
135%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$39.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$12.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$21.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$4.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$6.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
20%
|
CAGR 10-Years
23%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
See Also
What is Biomea Fusion Inc's Total Current Liabilities?
Total Current Liabilities
21.7m
USD
Based on the financial report for Dec 31, 2024, Biomea Fusion Inc's Total Current Liabilities amounts to 21.7m USD.
What is Biomea Fusion Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
135%
Over the last year, the Total Current Liabilities growth was -5%. The average annual Total Current Liabilities growth rates for Biomea Fusion Inc have been 68% over the past three years , 135% over the past five years .
